Nastasija Lezaic1,2, Geneviève Gore3, Colin B Josephson4, Samuel Wiebe4, Nathalie Jetté4,5, Mark R Keezer1,2,6. 1. Research Centre of the University of Montreal Hospital Centre, Montreal, Quebec, Canada. 2. Department of Neurosciences, University of Montreal, Montreal, Quebec, Canada. 3. Schulich Library of Physical Sciences, Life Sciences, and Engineering, McGill University, Montreal, Quebec, Canada. 4. Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. 5. Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York. 6. Department of Social and Preventative Medicine, University of Montreal, Montreal, Quebec, Canada.
Abstract
OBJECTIVE: To evaluate the efficacy and tolerability of antiepileptic drugs (AEDs) in elderly individuals with epilepsy. METHODS: We searched four electronic databases as well as bibliographies and conference abstracts. Published and unpublished, randomized, or quasirandomized trials reporting the use of AEDs in people aged at least 60 years with epilepsy were eligible for inclusion. Two authors independently carried out each stage of the review. Meta-analyses were performed using random-effects models. RESULTS: Three thousand four hundred seventeen titles and abstracts were reviewed. Eighteen studies evaluating 12 AEDs met all eligibility criteria. Ten studies, comprising 1999 subjects, were suitable for meta-analysis. Among the elderly with epilepsy, lamotrigine (LTG) is better tolerated relative to carbamazepine (pooled weighted risk ratio [RR] of experiencing withdrawal due to adverse events = 1.83, 95% confidence interval [CI] = 1.23-2.43). There is a higher probability, although with a 95% CI of borderline importance, of seizure freedom when comparing levetiracetam to LTG (RR = 0.83, 95% CI = 0.68-0.97). Single studies provide evidence for the efficacy and/or tolerability of other AEDs in the elderly, including brivaracetam, gabapentin, lacosamide, perampanel, and topiramate. The risk of bias of the included studies was frequently low or unclear, although there was on occasion a high risk of bias (especially with regard to selective reporting). SIGNIFICANCE: There is some evidence for AED use in the elderly with epilepsy. More evidence is required, comparing newer AEDs to prior generations as well as examining the effects of determinants such as frailty, to guide clinicians when treating this rapidly growing patient population. Wiley Periodicals, Inc.
OBJECTIVE: To evaluate the efficacy and tolerability of antiepileptic drugs (AEDs) in elderly individuals with epilepsy. METHODS: We searched four electronic databases as well as bibliographies and conference abstracts. Published and unpublished, randomized, or quasirandomized trials reporting the use of AEDs in people aged at least 60 years with epilepsy were eligible for inclusion. Two authors independently carried out each stage of the review. Meta-analyses were performed using random-effects models. RESULTS: Three thousand four hundred seventeen titles and abstracts were reviewed. Eighteen studies evaluating 12 AEDs met all eligibility criteria. Ten studies, comprising 1999 subjects, were suitable for meta-analysis. Among the elderly with epilepsy, lamotrigine (LTG) is better tolerated relative to carbamazepine (pooled weighted risk ratio [RR] of experiencing withdrawal due to adverse events = 1.83, 95% confidence interval [CI] = 1.23-2.43). There is a higher probability, although with a 95% CI of borderline importance, of seizure freedom when comparing levetiracetam to LTG (RR = 0.83, 95% CI = 0.68-0.97). Single studies provide evidence for the efficacy and/or tolerability of other AEDs in the elderly, including brivaracetam, gabapentin, lacosamide, perampanel, and topiramate. The risk of bias of the included studies was frequently low or unclear, although there was on occasion a high risk of bias (especially with regard to selective reporting). SIGNIFICANCE: There is some evidence for AED use in the elderly with epilepsy. More evidence is required, comparing newer AEDs to prior generations as well as examining the effects of determinants such as frailty, to guide clinicians when treating this rapidly growing patient population. Wiley Periodicals, Inc.
Authors: Samuel Waller Terman; Chun C Lin; Wesley T Kerr; Lindsey B DeLott; Brian C Callaghan; James F Burke Journal: Neurology Date: 2022-06-15 Impact factor: 11.800
Authors: Lidia M V R Moura; Jason R Smith; Zhiyu Yan; Deborah Blacker; Lee H Schwamm; Joseph P Newhouse; Sonia Hernandez-Diaz; John Hsu Journal: Pharmacoepidemiol Drug Saf Date: 2020-10-02 Impact factor: 2.890
Authors: Susana Ferrao Santos; Anna C Jansen; Lieven Lagae; Benjamin Legros; Sarah Weckhuysen; Paul Boon Journal: Acta Neurol Belg Date: 2020-10-13 Impact factor: 2.396